Clinical trials: Metastatic Gastric Carcinoma
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy…
- Trial name
- NCT05671822
- Testing
- SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Gastric Cancer
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062257
- Testing
- irofulven
- Where
- 6 sites in Australia, Hong Kong and 2 more
- Sponsor
- Cancer Therapeutics Research Group
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Adenocarcinoma
Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
This is an open-label, phase II study to evaluate the efficacy and safety of biweekly docetaxel and DeGramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.
- Trial name
- DaeMon (NCT01567618)
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Pancreas Cancer
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
This prospective, randomized, open-label and multicenter phase III study is aimed to estimate the survival benefit of Early Palliative Care (EPC) combined with standard oncology care including first-line chemotherapy…
- Conditions
- Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer
- Trial name
- EPIC-1511 (NCT02853474)
- Testing
- Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
- Where
- 20 sites in France
- Volunteers
- 480 people
- Sponsor
- Centre Oscar Lambret
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
TAC T-cells for the Treatment of HER2-positive Solid Tumors
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
- Trial name
- TACTIC-2 (NCT04727151)
- Testing
- TAC01-HER2, TAC01-HER2 plus pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Triumvira Immunologics, Inc.
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in patients with unresectable locally advanced or metastatic Gastric cancer failed to standard therapy.
- Trial name
- NCT02711969
- Testing
- Apatinib mesylate
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Bukwang Pharmaceutical
Stomach Neoplasms, Neoplasms Metastasis
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease are to be recruited in the study.
- Conditions
- Stomach Neoplasms, Neoplasms Metastasis, ERBB2 Gene Amplification
- Trial name
- NCT02004769
- Testing
- Trastuzumab, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sun Yat-sen University
Metastatic Gastric Adenocarcinoma
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs.
- Trial name
- NCT03990103
- Testing
- S1, Paclitaxel, Bevacizumab
- Where
- China
- Volunteers
- 66 people
- Sponsor
- China Medical University, China
OESOPHAGO-GASTRIC CARCINOMA
PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA
Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a cure.
- Trial name
- GASTFOX (NCT03006432)
- Testing
- Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu
- Where
- 134 sites in France, Martinique
- Volunteers
- 507 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma
- Trial name
- NCT01643499
- Testing
- oxaliplatin, irinotecan hydrochloride, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- University of Chicago
Lung Neoplasms, Pancreatic Neoplasms
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers.
- Conditions
- Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms
- Trial name
- NCT07035587
- Testing
- Serial Blood Sampling for Molecular Profiling, One-Time Blood Sampling for Molecular Profiling
- Where
- South Korea
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Breast Cancer, Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03847168
- Testing
- KN026
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Colorectal Neoplasms, Secondary
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
From 100 colorectal cancer patients being treated with FOLFIRI regimen or any kind of irinotecan containing regimen, blood samples for irinotecan and its metabolites levels and genotypes related with its metabolism will be…
- Trial name
- NCT00507143
- Testing
- irinotecan
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- National Cancer Center, Korea
Radiotherapy, Radiotherapy Side Effect
Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis
This phase II trial studies the side effects and response of pulsed low dose rate radiation therapy in treating gastric cancer patients with peritoneal metastasis.
- Conditions
- Radiotherapy, Radiotherapy Side Effect, Stomach Neoplasms
- Trial name
- NCT03061162
- Testing
- pulsed low dose rate radiation therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yang Yang